FDA Brief

Warning letters Drugs

FDA warning letter to

Joe Wise Pharmacy, Inc., dba Wise Pharmacy

High riskIssued Apr 15, 2021Posted Apr 27, 2021Division of Pharmaceutical Quality Operations IV

FDA warned Wise Pharmacy that its compounded sterile and non-sterile drugs were adulterated by insanitary compounding conditions.

What happened

After a June 12–21, 2019 inspection, FDA issued a Form FDA 483 and found serious deficiencies in how the pharmacy made sterile and non-sterile drugs. FDA said the ISO 5 workstation for sterile compounding sat in a non-classified room with a sink and dishwasher, and cited cleaning, water-quality, airflow, and environmental-monitoring failures. The pharmacy recalled all sterile drugs within expiry on July 10, 2019 and stopped sterile compounding that day.

What FDA found

  1. Sterile and non-sterile drugs were prepared under insanitary conditions that could contaminate them or make them harmful.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  2. The ISO 5 workstation used for sterile drugs was located and operated in a non-classified room, and non-sterile drugs were compounded in that same room.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  3. A sink and dishwasher in the room with the ISO 5 workstation were potential sources of microbial contamination.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  4. Cleaning practices for hoods handling hazardous and non-hazardous bulk drugs were deficient, so hazardous drugs were not adequately deactivated.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  5. The firm did not confirm that water quality was suitable for making non-sterile drugs.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  6. The firm lacked adequate dynamic smoke studies and its environmental monitoring was inadequate because samples were incubated at uncontrolled room temperature.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]

What FDA wants

FDA tells the pharmacy to respond in writing within 15 working days describing corrective steps, and to notify FDA 15 days before resuming any sterile drug production. If it does not plan to resume sterile production, it may say so; FDA also recommends a third-party consultant with sterile manufacturing expertise before resuming.

Who should pay attention

  • patient-safety and pharmacy quality teams
  • health systems and clinics that buy compounded drugs
  • compounding pharmacies and sterile-compounding operations

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk